Novartis has announced that the Phase IIIb MAXIMISE clinical trial of its Cosentyx...
Ipsen to restart dosing of palovarotene in FOP studies
Ipsen is set to restart palovarotene dosing in participants aged 14 and above in its clinical programme of fibrodysplasia ossificans progressiva (FOP).
Ipsen temporarily stops palovarotene dosing in FOP trials
Ipsen has paused the dosing of patients in Phase II extension and Phase III clinical studies of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).
Ipsen places hold on paediatric patients in palovarotene’s studies
Ipsen has placed a partial clinical hold on all global sites of the Phase II PVO-1A-202/204, PVO-2A-201, and Phase III PVO-1A-301 clinical trials assessing palovarotene.
FDA places Solid Biosciences’ DMD gene therapy trial on hold
The US Food and Drug Administration (FDA) has issued a clinical hold on Solid Biosciences’ Phase I/II IGNITE DMD study of SGT-001 to treat Duchenne muscular dystrophy (DMD).
BioCryst launches trial to treat fibrodysplasia ossificans progressiva
BioCryst Pharmaceuticals has initiated a Phase I clinical trial to treat fibrodysplasia ossificans progressiva (FOP) using its activin receptor-like kinase-2 (ALK-2) inhibitor, BCX9250.
Catalyst’s Phase III trial of Firdapse in CMS fails to meet goals
Catalyst Pharmaceuticals has reported top-line data from the Phase III CMS-001 clinical trial of Firdapse (amifampridine phosphate) as a symptomatic treatment of congenital myasthenic syndromes (CMS).
ReveraGen’s vamorolone improves muscle function in DMD trial
ReveraGen BioPharma has reported positive results from the ongoing VBP15-LTE clinical trial where vamorolone improved muscle function after 18 months of therapy in Duchenne muscular dystrophy (DMD) patients.
Ipsen reports positive data for Dysport to treat limb spasticity
Ipsen has reported positive data from the ENGAGE clinical trial of Dysport (abobotulinumtoxinA) in adults with upper and lower limb spastic hemiparesis.
Filgotinib shows improvements in rheumatoid arthritis trial
A Phase III clinical trial led by a Stanford University School of Medicine investigator has demonstrated that Gilead Sciences’ filgotinib led to substantial improvements in rheumatoid arthritis patients who did not respond to existing therapies.